Adicet Bio Inc. (ACET) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Adicet Bio Inc. (ACET)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.90

-0.01 (-1.01%)

At close: Jan 15, 2025, 11:53 AM

undefined% (undefined)

Bid	0.89
Market Cap	73.95M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.7
PE Ratio (ttm)	-0.53
Forward PE	n/a
Analyst	Buy

Ask	0.91
Volume	80,940
Avg. Volume (20D)	597,731
Open	0.92
Previous Close	0.91
Day's Range	0.89 - 0.94
52-Week Range	0.81 - 3.62
Beta	undefined

About ACET

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes AD...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 26, 2018

Employees 143

Stock Exchange NASDAQ

Ticker Symbol ACET

Website https://www.adicetbio.com

Analyst Forecast

According to 4 analyst ratings, the average rating for ACET stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 457.17% from the latest price.

Buy 75.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

3 months ago · Source

+6.43%

Adicet Bio shares are trading higher after the com... Unlock content with Pro Subscription

6 months ago · Source

+9.35%

Adicet Bio shares are trading higher after the company announced that the FDA granted it Fast Track Designation to ADI-270 for the potential treatment of patients with metastatic/advanced clear cell renal cell carcinoma.

News

1 week ago · businesswire.com

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun...

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic, gamma delta T cell therapies for autoimmu...